Laminaran

Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.

Product information

CAS Number: 9008-22-4

Molecular Weight: 518.44

Formula: C18H32NO16

Chemical Name: (3R,4S,5S,6R)-2-{[(3R,4S,5R,6R)-2-{[(3R,4S,5R,6R)-2-(hydrogeniooxy)-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol amine

Smiles: [N].OC1O[C@H](CO)[C@@H](O)[C@H](OC2O[C@H](CO)[C@@H](O)[C@H](OC3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H]2O)[C@H]1O

InChiKey: GJFKJJLVZGXQPX-PGDVRMGUSA-N

InChi: InChI=1S/C18H32O16.N/c19-1-4-7(22)10(25)11(26)17(31-4)34-15-9(24)6(3-21)32-18(13(15)28)33-14-8(23)5(2-20)30-16(29)12(14)27;/h4-29H,1-3H2;/t4-,5-,6-,7-,8-,9-,10+,11-,12-,13-,14+,15+,16?,17?,18?;/m1./s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 100 mg/mL (Need ultrasonic). H2O : 100 mg/mL (Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Laminaran (100-800 µg/mL; 24 hours) is not cytotoxic against normal epidermal cells JB6 Cl41 and human melanoma cells SK-MEL-28, the percentage of inhibition of living cells number is less than 15 % at concentrations range up to 800 µg/mL after 24 h of treatment. Laminaran (200 µg/mL; 24-72 hours)does not cause any growth inhibition of SK-MEL-28 cells after 24 and 48 h of treatment, but decreases cells proliferation by 36 % after 72 h of treatment. Laminaran (25-50 µg/mL; 24 hours) at low concentration does not influence the phosphorylation of c-Raf (Ser259), ERK1/2 (Tyr202/Tyr204), and MEK1/2 (Ser 221) kinases as well as total expression level of investigated proteins. But decreases p-MEK, p-ERK1/2 at 50 µg/mL.

In Vivo:

Laminaran (intravenous injection; 12.5, 25, and 50 mg/kg; 21 days) and OVA (50 μg) combination significanly decreases the tumor masses when it compares with the PBS-, OVA-, and laminarin-treated mice.

Products are for research use only. Not for human use.